CN116419924A - 用于治疗遗传性出血性毛细血管扩张症的变构akt抑制剂 - Google Patents

用于治疗遗传性出血性毛细血管扩张症的变构akt抑制剂 Download PDF

Info

Publication number
CN116419924A
CN116419924A CN202180066598.2A CN202180066598A CN116419924A CN 116419924 A CN116419924 A CN 116419924A CN 202180066598 A CN202180066598 A CN 202180066598A CN 116419924 A CN116419924 A CN 116419924A
Authority
CN
China
Prior art keywords
compound
hht
use according
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066598.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·皮卡德
P·赛恩特-梅扎尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedris Therapy GmbH
Original Assignee
Vedris Therapy GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedris Therapy GmbH filed Critical Vedris Therapy GmbH
Publication of CN116419924A publication Critical patent/CN116419924A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180066598.2A 2020-09-30 2021-09-29 用于治疗遗传性出血性毛细血管扩张症的变构akt抑制剂 Pending CN116419924A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015536.2 2020-09-30
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (1)

Publication Number Publication Date
CN116419924A true CN116419924A (zh) 2023-07-11

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066598.2A Pending CN116419924A (zh) 2020-09-30 2021-09-29 用于治疗遗传性出血性毛细血管扩张症的变构akt抑制剂

Country Status (13)

Country Link
US (1) US12466839B2 (https=)
EP (1) EP4221713A1 (https=)
JP (1) JP2023543993A (https=)
KR (1) KR20230080448A (https=)
CN (1) CN116419924A (https=)
AU (1) AU2021352108B2 (https=)
BR (1) BR112023004885A2 (https=)
CA (1) CA3192433A1 (https=)
CL (1) CL2023000926A1 (https=)
GB (1) GB2600384A (https=)
IL (1) IL301466A (https=)
MX (1) MX2023002996A (https=)
WO (1) WO2022069552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791708A (zh) * 2009-12-23 2012-11-21 阿尔麦克探索有限公司 Akt活性的抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EA201101186A1 (ru) 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791708A (zh) * 2009-12-23 2012-11-21 阿尔麦克探索有限公司 Akt活性的抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OLA, ROXANA，等: "1th International HHT Scientific Conference", 《ANGIOGENESIS》, vol. 18, no. 4, 31 December 2015 (2015-12-31), pages 525 - 575 *
ROXANA OLA，等: "SMAD4 Prevents Flow Induced Arterial-Venous Malformations by Inhibiting Casein Kinase 2", 《CIRCULATIONAHA》, vol. 138, no. 21, 5 July 2018 (2018-07-05), pages 2379 - 2394 *

Also Published As

Publication number Publication date
US20240092801A1 (en) 2024-03-21
AU2021352108A1 (en) 2023-05-11
GB2600384A (en) 2022-05-04
WO2022069552A1 (en) 2022-04-07
CL2023000926A1 (es) 2023-11-03
EP4221713A1 (en) 2023-08-09
JP2023543993A (ja) 2023-10-19
MX2023002996A (es) 2023-05-03
KR20230080448A (ko) 2023-06-07
CA3192433A1 (en) 2022-04-07
GB202015536D0 (en) 2020-11-11
AU2021352108B2 (en) 2026-04-02
US12466839B2 (en) 2025-11-11
BR112023004885A2 (pt) 2023-04-18
IL301466A (en) 2023-05-01
AU2021352108A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
EP3571203B1 (en) Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JP6141866B2 (ja) 置換ベンジルピラゾール類
KR101443651B1 (ko) Ｆｌｔ-3 키나제의 억제 방법
CN102137862B (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
JP6610562B2 (ja) ジヒドロインドリジノン誘導体
TW201620895A (zh) 新穎化合物（二）
CN105555767A (zh) 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
EA015942B1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
EP3710456B1 (en) Macrocyclic indole derivatives
TW201924676A (zh) Ｐ３８激酶抑制劑減少ｄｕｘ４及下游基因表現以供治療ｆｓｈｄ
JP2016535052A (ja) 線維素溶解の阻害剤としての（アザ）ピリドピラゾロピリミジノン類およびインダゾロピリミジノン類
CN116419924A (zh) 用于治疗遗传性出血性毛细血管扩张症的变构akt抑制剂
JP2017516860A (ja) Ａｒｆ６阻害剤並びにそれらの合成方法及び使用
CN115073421B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
KR20120018761A (ko) 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물
JP2017218449A (ja) ジヒドロインドリジノン誘導体を含有する医薬組成物
WO2014060763A1 (en) Compounds useful for treating ocular neovasculan
EA049324B1 (ru) Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии
JPWO2009110415A1 (ja) 併用剤
HK40074977A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40011855A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40011855B (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK1227852A1 (en) Substituted oxopyridine derivatives
EA025527B1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination